Vimarsana
Biggest News Aggregation in the World

Alyssa Li News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alyssa Li. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alyssa Li Today - Breaking & Trending Today

YS Biopharma Announces Results of Extraordinary General Meeting - Vimarsana News

YS Biopharma Announces Results of Extraordinary General Meeting

/PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility - Vimarsana News

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

GAITHERSBURG, Md., April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company

Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target - Vimarsana News

Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target

GAITHERSBURG, Md., Nov. 14, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company

Breakthrough Study Enhances Our Understanding of Visual Recognition Memory - Vimarsana News

Breakthrough Study Enhances Our Understanding of Visual Recognition Memory

Because figuring out what is new and what is familiar in what we see is such a critically important ability for prioritizing our attention, neuroscientists have spent decades trying to figure out how our brains are typically so good at it. Along the

YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine - Vimarsana News

YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the completion of subject enrollment in its Phase 3 clinical trial (the "Phase 3 Trial" or the "Trial") of the Company's PIKA Rabies Vaccine. The Trial, which will assess the safety, immunogenicity, and lot-to-lot consis

Source: yahoo.com